Apellis Pharmaceuticals, Inc.·4

Mar 14, 4:17 PM ET

Nicholson Nur 4

4 · Apellis Pharmaceuticals, Inc. · Filed Mar 14, 2024

Insider Transaction Report

Form 4
Period: 2024-03-13
Nicholson Nur
Chief Technical Officer
Transactions
  • Sale

    Common Stock

    2024-03-13$57.31/sh7,768$445,16159,739 total
  • Sale

    Common Stock

    2024-03-13$58.13/sh3,452$200,67756,287 total
Footnotes (2)
  • [F1]This transaction was executed in multiple trades at prices ranging from $56.91 - $57.75. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F2]This transaction was executed in multiple trades at prices ranging from $57.92 - $58.34. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Documents

1 file
  • 4
    form4.xmlPrimary

    PRIMARY DOCUMENT